| [1] |
中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2017)[J]. 中华骨质疏松和骨矿盐疾病杂志，2017, 10(5): 413-443.
|
| [2] |
Hampson G, Elder GJ, Cohen-Solal M, et al. A review and perspective on the assessment, management and prevention of fragility fractures in patients with osteoporosis and chronic kidney disease [J]. Endocrine, 2021, 73(3): 509-529.
|
| [3] |
Kim SM, Long J, Montez-Rath M, et al. Hip fracture in patients with non-dialysis-requiring chronic kidney disease [J]. J Bone Miner Res, 2016, 31(10): 1803-1809.
|
| [4] |
Hsu CY, Chen LR, Chen KH. Osteoporosis in patients with chronic kidney diseases: a systemic review [J]. Int J Mol Sci, 2020, 21(18): 6846.
|
| [5] |
国家肾脏疾病临床医学研究中心. 中国慢性肾脏病矿物质和骨异常诊治指南概要[J]. 肾脏病与透析肾移植杂志，2019, 28(1): 52-57.
|
| [6] |
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) [J]. Kidney Int Suppl, 2017, 7(1): 1-59.
|
| [7] |
Salam S, Gallagher O, Gossiel F, et al. Diagnostic accuracy of biomarkers and imaging for bone turnover in renal osteodystrophy [J]. J Am Soc Nephrol, 2018, 29(5): 1557-1565.
|
| [8] |
Steddon S, Sharples E. Renal association clinical practice guideline in mineral and bone disorders in CKD [J]. Nephron Clin Pract, 2011, 118(Suppl 1): c145-c152.
|
| [9] |
Evenepoel P, Cunningham J, Ferrari S, et al. European consensus statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4-G5D [J]. Nephrol Dial Transplant, 2021, 36(1): 42-59.
|
| [10] |
Miller PD. The kidney and bisphosphonates [J]. Bone, 2011, 49(1): 77-81.
|
| [11] |
Wang J, Yao M, Xu JH, et al. Bisphosphonates for prevention of osteopenia in kidney-transplant recipients: a systematic review of randomized controlled trials [J]. Osteoporos Int, 2016, 27(5): 1683-1690.
|
| [12] |
Toth-Manikowski SM, Francis JM, Gautam A, et al. Outcomes of bisphosphonate therapy in kidney transplant recipients: a systematic review and meta-analysis [J]. Clin Transplant, 2016, 30(9): 1090-1096.
|
| [13] |
Swallow EA, Aref MW, Metzger CE, et al. Skeletal levels of bisphosphonate in the setting of chronic kidney disease are independent of remodeling rate and lower with fractionated dosing [J]. Bone, 2019, 127: 419-426.
|
| [14] |
Robinson DE, Ali MS, Pallares N, et al. Safety of oral bisphosphonates in moderate-to-severe chronic kidney disease: a binational cohort analysis [J]. J Bone Miner Res, 2021, 36(5): 820-832.
|
| [15] |
Roughead EE, Kerr M, Moffat A, et al. Medicine- induced acute kidney injury findings from spontaneous reporting systems, sequence symmetry analysis and a case-control study with a focus on medicines used in primary care [J]. Drug Saf, 2022, 45(11): 1413-1421.
|
| [16] |
Hauck D, Nery L, O′Connell R, et al. Bisphosphonates and bone mineral density in patients with end-stage kidney disease and renal transplants: a 15-year single-centre experience [J]. Bone Rep, 2022, 16: 101178.
|
| [17] |
Alarkawi D, Ali MS, Bliuc D, et al. Oral bisphosphonate use and all-cause mortality in patients with moderate-severe (grade 3B-5D) chronic kidney disease: a population-based cohort study [J]. J Bone Miner Res, 2020, 35(5): 894-900.
|
| [18] |
Ali MS, Ernst M, Robinson DE, et al. Alendronate use and bone mineral density gains in women with moderate-severe (stages 3B-5) chronic kidney disease: an open cohort multivariable and propensity score analysis from Funen, Denmark [J]. Arch Osteoporos, 2020, 15(1): 81.
|
| [19] |
Malluche H. Renal osteodystrophy: an individual management approach [DB/OL]. 2015:
URL
|
| [20] |
Chen X, Wang Z, Duan N, et al. Osteoblast-osteoclast interactions [J]. Connect Tissue Res, 2018, 59(2): 99-107.
|
| [21] |
夏维波. 地舒单抗在骨质疏松症临床合理用药的中国专家建议[J]. 中华骨质疏松和骨矿盐疾病杂志，2020, 13(6): 499-508.
|
| [22] |
Block GA, Bone HG, Fang L, et al. A single-dose study of denosumab in patients with various degrees of renal impairment [J]. J Bone Miner Res, 2012, 27(7): 1471-1479.
|
| [23] |
Gopaul A, Kanagalingam T, Thain J, et al. Denosumab in chronic kidney disease: a narrative review of treatment efficacy and safety [J]. Arch Osteoporos, 2021, 16(1): 116.
|
| [24] |
Symonds C, Kline G. Warning of an increased risk of vertebral fracture after stopping denosumab [J]. CMAJ, 2018, 190(16): E485-E486.
|
| [25] |
Marjoribanks J, Farquhar C, Roberts H, et al. Long-term hormone therapy for perimenopausal and postmenopausal women [J]. Cochrane Database Syst Rev, 2017, 1(1): CD004143.
|
| [26] |
张萌萌. 雌激素与雌激素受体骨代谢调节作用[J]. 中国骨质疏松杂志，2019, 25(5): 704-708.
|
| [27] |
Tanaka M, Itoh K, Matsushita K, et al. Effects of raloxifene on bone mineral metabolism in postmenopausal Japanese women on hemodialysis [J]. Ther Apher Dial, 2011, 15(Suppl 1): 62-66.
|
| [28] |
Haghverdi F, Farbodara T, Mortaji S, et al. Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5 [J]. Iran J Kidney Dis, 2014, 8(6): 461-466.
|
| [29] |
Ma HY, Chen S, Lu LL, et al. Raloxifene in the treatment of osteoporosis in postmenopausal women with end-stage renal disease: a systematic review and meta-analysis [J]. Horm Metab Res, 2021, 53(11): 730-737.
|
| [30] |
Srinivasan A, Wong FK, Karponis D. Calcitonin: a useful old friend [J]. J Musculoskelet Neuronal Interact, 2020, 20(4): 600-609.
|
| [31] |
李映燕，尹良红，刘璠娜，等. 降钙素治疗慢性肾脏病-矿物质和骨异常的研究进展[J]. 临床肾脏病杂志，2018, 18(9): 579-581.
|
| [32] |
黄应钟，杨立进. 序贯抗骨质疏松对老年股骨粗隆间骨折愈合时间及再骨折的影响[J]. 医学信息，2021, 34(18): 94-98.
|
| [33] |
石书梅，赵学智，陆烈，等. 降钙素及二膦酸盐治疗血液透析患者肾性骨病的长期疗效[J]. 中华肾脏病杂志，2009, 25(5): 341-344.
|
| [34] |
赵俊，徐文，倪倍倍，等. 特立帕肽致不良反应文献分析[J]. 中国医院药学杂志，2021, 41(12): 1249-1254.
|
| [35] |
Nishikawa A, Yoshiki F, Taketsuna M, et al. Safety and effectiveness of daily teriparatide for osteoporosis in patients with severe stages of chronic kidney disease: post hoc analysis of a postmarketing observational study [J]. Clin Interv Aging, 2016, 11: 1653-1659.
|
| [36] |
Yamamoto J, Nakazawa D, Nishio S, et al. Impact of weekly teriparatide on the bone and mineral metabolism in hemodialysis patients with relatively low serum parathyroid hormone: a pilot study [J]. Ther Apher Dial, 2020, 24(2): 146-153.
|
| [37] |
Ginsberg C, Ix JH. Diagnosis and management of osteoporosis in advanced kidney disease: a review [J]. Am J Kidney Dis, 2022, 79(3): 427-436.
|
| [38] |
Bandeira L, Lewiecki EM, Bilezikian JP. Romosozumab for the treatment of osteoporosis [J]. Expert Opin Biol Ther, 2017, 17(2): 255-263.
|
| [39] |
朱冬燕，刘海岭，魏雅娟. 骨硬化蛋白在慢性肾脏病-矿物质和骨代谢异常中的研究进展[J]. 中国中西医结合肾病杂志，2020, 21(9)：832-835.
|
| [40] |
Sato M, Inaba M, Yamada S, et al. Efficacy of romosozumab in patients with osteoporosis on maintenance hemodialysis in Japan; an observational study [J]. J Bone Miner Metab, 2021, 39(6): 1082-1090.
|